| Univariate analysis | Multivariate analysis | ||||
---|---|---|---|---|---|---|
HR | 95% CI | P | HR | 95% CI | P | |
TCGA training cohort | ||||||
 Age | 1.023 | 0.999–1.049 | 0.06 | 1.033 | 1.008–1.058 | 0.009 |
 TNM stage | 2.67 | 1.918–3.718 |  < 0.001 | 2.73 | 1.911–3.9 |  < 0.001 |
 CAF signature | 4.418 | 2.521–7.744 |  < 0.001 | 3.161 | 1.828–5.468 |  < 0.001 |
TCGA validation cohort | ||||||
 Age | 1.061 | 1.024–1.099 | 0.001 | 1.058 | 1.023–1.094 | 0.001 |
 TNM stage | 2.363 | 1.566–3.564 |  < 0.001 | 2.391 | 1.566–3.651 |  < 0.001 |
 CAF signature | 2.323 | 1.094–4.932 | 0.028 | 1.334 | 0.609–2.920 | 0.471 |
TCGA total cohort | ||||||
 Age | 1.036 | 1.016–1.057 |  < 0.001 | 1.039 | 1.02–1.059 |  < 0.001 |
 TNM stage | 2.553 | 1.973–3.304 |  < 0.001 | 2.568 | 1.962–3.361 |  < 0.001 |
 CAF signature | 3.45 | 2.212–5.381 |  < 0.001 | 2.261 | 1.454–3.516 |  < 0.001 |
GSE39582 cohort | ||||||
 Age | 1.039 | 1.024–1.053 |  < 0.001 | 1.037 | 1.023–1.052 |  < 0.001 |
 TNM stage | 1.688 | 1.315–2.167 |  < 0.001 | 1.646 | 1.272–2.13 |  < 0.001 |
 CAF signature | 1.744 | 1.277–2.382 |  < 0.001 | 1.455 | 1.055–2.007 | 0.022 |
GSE17536 cohort | ||||||
 Age | 1.006 | 0.988–1.025 | 0.492 | 1.027 | 1.006–1.047 | 0.01 |
 TNM stage | 2.855 | 2.112–3.859 |  < 0.001 | 3.323 | 2.373–4.653 |  < 0.001 |
 CAF signature | 2.553 | 1.413–4.613 | 0.002 | 3.018 | 1.644–5.539 |  < 0.001 |
HColA095Su01 cohort | ||||||
 Age | 0.995 | 0.969–1.022 | 0.704 | 0.997 | 0.97–1.026 | 0.86 |
 TNM stage | 1.069 | 0.631–1.811 | 0.803 | 1.239 | 0.714–2.148 | 0.446 |
 CAF signature | 1.003 | 1.001–1.005 | 0.011 | 1.003 | 1.001–1.005 | 0.014 |